Xin Lang Cai Jing·2025-10-15 02:32Core Viewpoint - The stock of Haiprui has shown a mixed performance in recent trading sessions, with a year-to-date increase of 13.12% but a decline in the last five, twenty, and sixty days [1][2]. Company Overview - Haiprui Pharmaceutical Group Co., Ltd. is located in Nanshan District, Shenzhen, Guangdong Province, and was established on April 21, 1998. The company was listed on May 6, 2010 [1]. - The main business activities include research, production, and sales of heparin sodium raw materials and downstream low molecular weight heparin products. The revenue composition is as follows: formulations 63.06%, CDMO 18.59%, heparin sodium and low molecular weight heparin raw materials 16.05%, and others 2.30% [1]. Financial Performance - As of June 30, 2025, Haiprui reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%. The net profit attributable to shareholders was 422 million yuan, down 36.44% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 4.21 billion yuan, with 514 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 7.29% to 26,300, with an average of 0 circulating shares per person [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 11.3176 million shares, an increase of 6.3765 million shares compared to the previous period [3].